Highlights Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.01 ^USD	+2.04%		-0.79%	-44.27%

Mar. 20	ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	CI
Mar. 07	Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	Feb. 15	MT
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	Feb. 15	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	Feb. 15	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	Feb. 15	CI
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	Feb. 15	RE
Kidney drug developer Aurinia fails to clinch a sale, sources say	Feb. 15	RE
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	Feb. 14	CI
Aurinia Pharmaceuticals Reports Higher Q4, 2023 Preliminary Revenue; Shares Rise	Jan. 05	MT
Aurinia Pharmaceuticals Submits Investigational New Drug Application for AUR200	Dec. 20	MT
Aurinia Pharmaceuticals Inc. Submits IND Application to US Food & Drug Administration for AUR 200	Dec. 20	CI
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan	Nov. 13	MT
Aurinia Pharmaceuticals Inc. Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis	Nov. 02	CI
Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Fiscal Year 2023	Nov. 02	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q3 Revenue $54.5M, vs. Street Est of $38.5M	Nov. 02	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Aurinia Pharmaceuticals Inc. Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis	23-10-26	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2023	23-08-03	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Reports Q2 Revenue $41.5M, vs. Street Est of $37.5M	23-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Highlights

Filters